Ovarian Neoplasms: Clinical Trials

307 trials for Ovarian Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

121 completed, 54 recruiting, 47 unknown, 33 active not recruiting. 307 Phase 3, 29 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3307Completed 121, Recruiting 54, Unknown 47, Active not recruiting 33, Terminated 29, Not yet recruiting 13, Withdrawn 9, Suspended 1
Phase 229Recruiting 9, Completed 8, Unknown 4, Active not recruiting 3, Terminated 3, Not yet recruiting 1, Withdrawn 1

Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms

Trials (filtered) newest first · largest first

All 307 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 3Not yet recruitingDaiichi Sankyo6002027-03-312026-11-13
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
INCB123667, Bevacizumab, Placebo - Ovarian Cancer
Phase 3Not yet recruitingIncyte Corporation5902026-12-012026-10-02
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.4202026-12-012026-11-09
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer
Phase 3Not yet recruitingGenmab6022026-11-012026-10-05
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
trastuzumab, bevacizumab - Ovarian Cancer
Phase 3RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.4202026-10-202026-11-04
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy - Ovarian Cancer
Phase 3RecruitingChinese PLA General Hospital1202026-10-122026-09-16
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer
Phase 3RecruitingMerck Sharp & Dohme LLC6462026-10-072026-11-17
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Mocertatug rezetecan, Bevacizumab - Ovarian Neoplasms
Phase 3RecruitingGlaxoSmithKline7202026-10-022026-11-03
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers
Phase 2 / Phase 3RecruitingGE Healthcare1752026-10-012026-06-17
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 3Not yet recruitingBeOne Medicines6002026-10-012026-09-10
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer
Phase 3RecruitingAstraZeneca6002026-09-242026-10-16
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms
Phase 3RecruitingMerck Sharp & Dohme LLC8022026-09-182026-11-17
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer
Phase 3RecruitingAstraZeneca9502026-09-162026-11-06
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel - Ovarian Neoplasms
Phase 3RecruitingGlaxoSmithKline6902026-09-082026-10-01
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
Phase 3RecruitingGenmab6882026-08-282026-11-04
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.4042026-07-012026-06-29
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer
Phase 3RecruitingGenmab822026-06-262026-11-03
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms
Phase 3RecruitingGlaxoSmithKline4502026-06-182026-10-15
Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
Tiaoshen Anti-cancer Granules, Placebo Granules, Cognitive Behavioral Therapy for Insomnia - Ovarian Neoplasms Malignant, Sleep Initiation and Maintenance Disorders
Phase 2 / Phase 3Not yet recruitingShanghai Municipal Hospital of Traditional Chinese Medicine3602026-05-012026-04-24
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Investigator's choice of Chemotherapy, Azenosertib - Ovarian Cancer
Phase 3RecruitingK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc4202026-04-172026-11-09

Showing 20 of 307. Sign in to see all of them.

Narrower conditions

Fallopian Tube Neoplasms (108)  ·  Carcinoma, Ovarian Epithelial (97)  ·  Neoplasms (26)  ·  Breast Neoplasms (25)  ·  Endometrial Neoplasms (15)  ·  Peritoneal Neoplasms (15)  ·  Recurrence (14)  ·  Uterine Cervical Neoplasms (14)  ·  Brenner Tumor (13)  ·  Testicular Neoplasms (13)  ·  Multiple Myeloma (12)  ·  Burkitt Lymphoma (11)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (11)  ·  Blast Crisis (10)

Broader conditions

Adnexal Diseases (307)  ·  Endocrine System Diseases (307)  ·  Female Urogenital Diseases (307)  ·  Female Urogenital Diseases and Pregnancy Complications (307)  ·  Genital Diseases (307)  ·  Gonadal Disorders (307)  ·  Urogenital Diseases (307)  ·  Urogenital Neoplasms (307)  ·  Genital Diseases, Female (306)  ·  Ovarian Diseases (306)  ·  Genital Neoplasms, Female (304)  ·  Neoplasms by Site (304)  ·  Endocrine Gland Neoplasms (302)  ·  Neoplasms (281)  ·  Neoplasms by Histologic Type (127)

Interventions

Paclitaxel (98)  ·  Carboplatin (75)  ·  Bevacizumab (49)  ·  liposomal doxorubicin (40)  ·  Topotecan (36)  ·  Gemcitabine (29)  ·  Cisplatin (20)  ·  olaparib (19)  ·  Drug Therapy (16)  ·  Taxes (15)  ·  Doxorubicin (14)  ·  Hyperthermic Intraperitoneal Chemotherapy (9)  ·  niraparib (9)  ·  Chemotherapy, Adjuvant (8)  ·  1-dodecylpyridoxal (7)

Sponsors

AstraZeneca (13)  ·  National Cancer Institute (NCI) (10)  ·  Gynecologic Oncology Group (9)  ·  AGO Study Group (8)  ·  Medical Research Council (7)  ·  Merck Sharp & Dohme LLC (7)  ·  European Organisation for Research and Treatment of Cancer - EORTC (6)  ·  Genmab (5)  ·  Hoffmann-La Roche (5)  ·  National Cancer Institute, Naples (5)  ·  Amgen (4)  ·  Jiangsu HengRui Medicine Co., Ltd. (4)  ·  North Eastern German Society of Gynaecological Oncology (4)  ·  Pfizer (4)  ·  Tesaro, Inc. (4)

Countries

United States (131)  ·  Italy (85)  ·  United Kingdom (78)  ·  Spain (74)  ·  Canada (70)  ·  France (70)  ·  Belgium (67)  ·  China (67)  ·  Germany (66)  ·  South Korea (61)  ·  Australia (51)  ·  Poland (50)  ·  Israel (45)  ·  Japan (45)  ·  Denmark (41)

Top investigators

Francesco Perrone, M.D., Ph.D. (3)  ·  Ignace B. Vergote, MD, PhD (3)  ·  Jacobus Pfisterer, MD (3)  ·  Jalid Sehouli (3)  ·  Sandro Pignata, M.D., Ph.D. (3)  ·  Cary Presant, MD (2)  ·  Ciro Gallo, M.D., Ph.D. (2)

Results publications

PMID 37185961, PMID 37407274, PMID 35170751, PMID 39695768, PMID 21941283, PMID 30633128, PMID 16882940, PMID 16966687, PMID 20818904, PMID 33960681, PMID 39019698, PMID 10481771, PMID 10655437, PMID 11165136, PMID 11304695, PMID 11479630, PMID 12826431, PMID 12829663, PMID 12860964, PMID 14656276, PMID 15459300, PMID 15547181, PMID 15839957, PMID 16110020, PMID 16148284, PMID 16239238, PMID 16314640, PMID 16368440, PMID 16394300, PMID 16515585, PMID 16791447, PMID 16849762, PMID 16912194, PMID 17264340, PMID 17698804, PMID 17704410, PMID 17906207, PMID 17925548, PMID 17949799, PMID 18336399, PMID 18430468, PMID 18640939, PMID 18768432, PMID 18801470, PMID 19169758, PMID 19224848, PMID 19270260, PMID 19427025, PMID 19596139, PMID 19767092

NIH funding

U10CA180868 (12), 2025 (10), U10CA027469 (9), 2018 (6), 2023 (6), 2008 (5), 2017 (4), 2009 (3), 2015 (3), 2019 (3), 2016 (2), U10CA032102 (2), U10CA101165 (2), 2004 (1), 2005 (1)